Clinical Trial Detail

NCT ID NCT02192541
Title Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements no
Sponsors National Cancer Institute (NCI)
Indications

non-small cell lung carcinoma

sarcoma

urinary system cancer

gastrointestinal system cancer

Therapies

Aflibercept + Ganetespib

Age Groups: adult

No variant requirements are available.